BIOMARIN PHARMACEUTICAL INC.

(BMRN)
  Report
Real-time Estimate Cboe BZX  -  12:19 2022-08-16 pm EDT
95.82 USD   -1.16%
08/12INSIDER SELL : Biomarin Pharmaceutical
MT
08/09Piper Sandler Adjusts Price Target on BioMarin Pharmaceutical to $128 From $125, Reiterates Overweight Rating
MT
08/04BIOMARIN PHARMACEUTICAL INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Sector Update: Health Care Stocks Outpacing Broader Markets, Other Sectors to Upside

06/22/2022 | 01:42pm EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
ATHIRA PHARMA, INC. 1.67% 3.965 Delayed Quote.-70.07%
BIOMARIN PHARMACEUTICAL INC. -1.16% 95.77 Delayed Quote.9.72%
ENANTA PHARMACEUTICALS, INC. -1.68% 69.275 Delayed Quote.-5.78%
EURO / BRAZILIAN REAL (EUR/BRL) 1.04% 5.2332 Delayed Quote.-17.97%
NASDAQ COMPOSITE -0.02% 13125 Real-time Quote.-16.09%
PFIZER, INC. -0.15% 49.645 Delayed Quote.-15.75%
All news about BIOMARIN PHARMACEUTICAL INC.
08/12INSIDER SELL : Biomarin Pharmaceutical
MT
08/09Piper Sandler Adjusts Price Target on BioMarin Pharmaceutical to $128 From $125, Reiter..
MT
08/04BIOMARIN PHARMACEUTICAL INC Management's Discussion and Analysis of Financial Conditio..
AQ
08/04Morgan Stanley Adjusts BioMarin Pharmaceutical's Price Target to $117 from $113, Keeps ..
MT
08/04Credit Suisse Raises BioMarin Pharmaceutical's Price Target to $111 from $107 After Hig..
MT
08/04SVB Securities Raises BioMarin Pharmaceutical's Price Target to $122 From $115, Reitera..
MT
08/04Goldman Sachs Trims BioMarin Pharmaceutical's Price Target to $174 From $176, Maintains..
MT
08/04Oppenheimer Adjusts BioMarin Pharmaceutical's Price Target to $92 From $94, Maintains P..
MT
08/04Barclays Adjusts BioMarin Pharmaceutical's Price Target to $125 From $112, Keeps Overwe..
MT
08/03BIOMARIN PHARMACEUTICAL : Announces Record Revenues in Second Quarter 2022; Increases Full..
PU
More news
Analyst Recommendations on BIOMARIN PHARMACEUTICAL INC.
More recommendations
Financials (USD)
Sales 2022 2 122 M - -
Net income 2022 146 M - -
Net cash 2022 459 M - -
P/E ratio 2022 129x
Yield 2022 -
Capitalization 17 933 M 17 933 M -
EV / Sales 2022 8,24x
EV / Sales 2023 6,44x
Nbr of Employees 3 045
Free-Float 99,4%
Chart BIOMARIN PHARMACEUTICAL INC.
Duration : Period :
BioMarin Pharmaceutical Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOMARIN PHARMACEUTICAL INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 23
Last Close Price 96,94 $
Average target price 114,14 $
Spread / Average Target 17,7%
EPS Revisions
Managers and Directors
Jean-Jacques Bienaimé Chairman & Chief Executive Officer
Brian R. Mueller Chief Financial Officer & Executive VP-Finance
Henry J. Fuchs President-Worldwide Research & Development
Eduardo E. von Pervieux Chief Information Officer
C. Greg Guyer Chief Technical Officer & Executive Vice President
Sector and Competitors